A real world study of Thymosin a1 with immunocheckpoint inhibitors in the treatment of malignant tumors

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043329

Enrollment

Unknown

Registered

2021-02-10

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumors

Interventions

The treatment group:immunocheckpoint inhibitors with Thymosin a1 1.6mg biw

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the multidisciplinary diagnosis and treatment of common malignant tumors, patients who meet the diagnostic criteria of various malignant tumors.

Exclusion criteria

Exclusion criteria: 1. Patients with other serious diseases; 2. Patients who lack clear consciousness.

Design outcomes

Primary

Measure	Time frame
OS;PFS;ORR;CD4+/CD8+;T lymphocyte ratio;B lymphocyte ratio;Assisted induction T lymphocytes ratio;Inhibition toxic T lymphocytes ratio;NK cell ratio;The absolute value of Assisted induction T lymphocytes;	—

Countries

China

Contacts

Public ContactLimin Zhao

General Hospital of Heilongjiang Province Land Reclamation Bureau,Harbin

zhao-limin@126.com+86 15546210787

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026